These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 31276989)

  • 1. Stereotactic body radiation therapy with optional focal lesion ablative microboost in prostate cancer: Topical review and multicenter consensus.
    Draulans C; De Roover R; van der Heide UA; Haustermans K; Pos F; Smeenk RJ; De Boer H; Depuydt T; Kunze-Busch M; Isebaert S; Kerkmeijer L
    Radiother Oncol; 2019 Nov; 140():131-142. PubMed ID: 31276989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
    Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
    Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer.
    Draulans C; van der Heide UA; Haustermans K; Pos FJ; van der Voort van Zyp J; De Boer H; Groen VH; Monninkhof EM; Smeenk RJ; Kunze-Busch M; De Roover R; Depuydt T; Isebaert S; Kerkmeijer LGW
    Radiother Oncol; 2020 Jun; 147():92-98. PubMed ID: 32247206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial.
    De Cock L; Draulans C; Pos FJ; Isebaert S; De Roover R; van der Heide UA; Smeenk RJ; Kunze-Busch M; van der Voort van Zyp J; de Boer H; Kerkmeijer LGW; Haustermans K
    Radiother Oncol; 2023 Aug; 185():109713. PubMed ID: 37178932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
    Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
    BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toxicity and Patient-Reported Quality-of-Life Outcomes After Prostate Stereotactic Body Radiation Therapy With Focal Boost to Magnetic Resonance Imaging-Identified Prostate Cancer Lesions: Results of a Phase 2 Trial.
    Morris BA; Holmes EE; Anger NJ; Cooley G; Schuster JM; Hurst N; Baschnagel AM; Bassetti MF; Blitzer GC; Chappell RJ; Bayliss RA; Morris ZS; Ritter MA; Floberg JM
    Int J Radiat Oncol Biol Phys; 2023 Nov; 117(3):613-623. PubMed ID: 37179035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
    Leeman JE; Shin KY; Chen YH; Mak RH; Nguyen PL; D'Amico AV; Martin NE
    Cancer; 2023 Oct; 129(19):3044-3052. PubMed ID: 37485697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.
    Kerkmeijer LGW; Groen VH; Pos FJ; Haustermans K; Monninkhof EM; Smeenk RJ; Kunze-Busch M; de Boer JCJ; van der Voort van Zijp J; van Vulpen M; Draulans C; van den Bergh L; Isebaert S; van der Heide UA
    J Clin Oncol; 2021 Mar; 39(7):787-796. PubMed ID: 33471548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Safety and Efficacy of Salvage Stereotactic Radiation Therapy in Patients with Intraprostatic Tumor Recurrence After Previous External Radiation Therapy: Phase 1 Results from the GETUG-AFU 31 Study.
    Pasquier D; Lacornerie T; Supiot S; Pommier P; Quivrin M; Simon JM; Loos G; Meyer E; Calais G; Peiffert D; Vandendorpe B; Aymes E; Leguillette C; Brihoum M; Nenan S; Cormier L; Le Deley MC; Lartigau EF
    Eur Urol Oncol; 2023 Aug; 6(4):399-405. PubMed ID: 36754722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: a dose-escalation trial (DESTROY-4).
    Deodato F; Ferro M; Bonome P; Pezzulla D; Romano C; Buwenge M; Cilla S; Morganti AG; Macchia G
    Strahlenther Onkol; 2024 Mar; 200(3):239-249. PubMed ID: 38180492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial.
    Zilli T; Scorsetti M; Zwahlen D; Franzese C; Förster R; Giaj-Levra N; Koutsouvelis N; Bertaut A; Zimmermann M; D'Agostino GR; Alongi F; Guckenberger M; Miralbell R
    Radiat Oncol; 2018 Sep; 13(1):166. PubMed ID: 30180867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors, efficacy, and toxicity of involved-node stereotactic body radiation therapy for lymph node oligorecurrent prostate cancer : An investigation of 117 pelvic lymph nodes.
    Cozzi S; Botti A; Timon G; Blandino G; Najafi M; Manicone M; Bardoscia L; Ruggieri MP; Ciammella P; Iotti C
    Strahlenther Onkol; 2022 Aug; 198(8):700-709. PubMed ID: 34757443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
    Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.
    Yu JB; Cramer LD; Herrin J; Soulos PR; Potosky AL; Gross CP
    J Clin Oncol; 2014 Apr; 32(12):1195-201. PubMed ID: 24616315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study.
    Alayed Y; Loblaw A; Chu W; Al-Hanaqta M; Chiang A; Jain S; Chung H; Vesprini D; Morton G; Ravi A; Davidson M; Deabreu A; Mamedov A; Zhang L; Erler D; Cheung P
    Int J Radiat Oncol Biol Phys; 2019 Aug; 104(5):1066-1073. PubMed ID: 31002941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review.
    Foerster R; Zwahlen DR; Buchali A; Tang H; Schroeder C; Windisch P; Vu E; Akbaba S; Bostel T; Sprave T; Zamboglou C; Zilli T; Stelmes JJ; Telkhade T; Murthy V
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33673077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature.
    Le Guevelou J; Bosetti DG; Castronovo F; Angrisani A; de Crevoisier R; Zilli T
    World J Urol; 2023 Nov; 41(11):3287-3299. PubMed ID: 37668718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol.
    Pasquier D; Le Deley MC; Tresch E; Cormier L; Duterque M; Nenan S; Lartigau E
    BMJ Open; 2019 Aug; 9(8):e026666. PubMed ID: 31377694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Prospective Single-Arm Phase 2 Study of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for Prostate Cancer: Early Toxicity Results.
    Bruynzeel AME; Tetar SU; Oei SS; Senan S; Haasbeek CJA; Spoelstra FOB; Piet AHM; Meijnen P; Bakker van der Jagt MAB; Fraikin T; Slotman BJ; van Moorselaar RJA; Lagerwaard FJ
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1086-1094. PubMed ID: 31419510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.